Maze Therapeutics, Inc.
NASDAQ:MAZEBiotechnology
+$0.18 today
- Market cap
- $1.71B
- Beta
- 2.26
- P/E (TTM)
- -11.0
- EPS (TTM)
- -$2.27
Volume 0.71M
Average 0.84M
MAZE Other Current Liabilities
Short-term obligations not reported separately, such as accrued expenses.
Maze Therapeutics, Inc.NASDAQ: MAZE
Other Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Other current liabilities falls 25.5% from a year ago
Other current liabilities stood at $5.42M at the end of Q1 FY2026, down 25.5% from a year earlier and down 50.1% from the prior quarter. Over 3 fiscal years it compounded at +13.2% a year.
Context
- Other current liabilities amounted to 1.3% of total assets at the end of Q1 FY2026, down 0.9 pp from a year earlier.
- Other current liabilities increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether other current liabilities keeps falling in the next quarterly balance sheet after a -25.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 10.85M USD
- Year-over-year change
- +80.3%
- 3-year CAGR
- +13.2%
| Period | Period end | Other Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 10.85M | +80.3% |
| FY2024 | 2024-12-31 | 6.02M | +105.7% |
| FY2023 | 2023-12-31 | 2.93M | -60.9% |
| FY2022 | 2022-12-31 | 7.49M | — |
Other Current Liabilities vs competitors
How MAZE compares with its peers on the latest reported figures
- Peers report in different currencies, so other current liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -25.5% is the 6th highest of 8, against a peer median of +30.9%.
- Other current liabilities amounts to 1.3% of total assets for MAZE, versus a peer median of 3.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $473.08M USD | +31.8% | +17.1% | 14.6% | |
| Sep 2026 | $204.6M USD | +521.1% | -2.3% | 24.1% | |
SEPNSepterna, Inc. | Sep 2026 | $26.4M USD | -57.2% | +51.2% | 4.3% |
| Mar 2026 | $9.38M USD | +30.9% | +87.7% | 1.9% | |
| Dec 2025 | €8.29M EUR | -88.7% | +53.8% | 3.3% | |
| Mar 2026 | $5.42M USD | -25.5% | +13.2% | 1.3% | |
| Mar 2026 | $741K USD | +117.3% | +27.4% | 1.4% | |
BIOABioAge Labs, Inc. | Mar 2026 | $714K USD | +28.0% | +179.7% | 0.2% |
| Peer median (excluding MAZE) | — | +30.9% | +51.2% | 3.3% | |
Competitors are the stored peer set for MAZE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Maze Therapeutics, Inc.
NASDAQ:MAZE
Intrinsic Alpha fair value
Locked
Current Price
$31.20
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.